OIG Greenlights Sponsor's Proposal for Medicare Cost-Sharing Subsidies in Clinical Trial
- March 18, 2022
The Department of Health and Human Services Office of Inspector General (OIG) won’t impose administrative sanctions in connection with a device manufacturer’s proposal to subsidize certain Medicare cost-sharing obligations in a clinical trial for an investigational therapy that uses a patient’s own cells for the treatment of ischemic systolic heart failure, according to an advisory opinion posted March 16.
ARTICLE TAGS
You must be logged in to access this content.